CRBU

Caribou Biosciences' stock has experienced volatility in the past six months. The stock declined approximately 10% over the last 30 days due to market fluctuations and financing concerns, but rose about 12% over the past quarter due to positive earnings and pipeline progress. Key events impacting the stock include a Q4 2025 earnings beat, vispa-cel Phase 3 plans, CB-011 RMAT designation and clinical data, concerns about cash burn and capital needs, Q1 2026 financial results, and regaining Nasdaq compliance.